Sodexo Canada: The global leader who believes the difference a day makes
Founded in Marseille in 1966, and now operating in 53 countries, Sodexo provides facilities services that drive positive
Barclay Restorations DKI: The longest running insurance restoration company in Greater Vancouver
Locally owned-and operated and serving Metro Vancouver and the Fraser Valley, Barclay Restorations DKI is a full-service restoration CDW Canada: Helping small businesses use IT security to prepare, defend, and respond
Established in 2003, CDW Canada is a leading provider of technology solutions for business, government, education, and healthcare, Stamped Engineering Corporation: High quality, fit for purpose engineering services
Specializing in design engineering that is customized to the needs of the client, Stamped Engineering Corporation is a Alpine Building Maintenance: Customized cleaning solutions
Founded in 1980 in the interior of British Columbia, family-owned building services company Alpine Building Maintenance has evolved Case Design/Remodeling Halifax: Flawless design and execution
With two decades of experience, Case Design/Remodeling is a design-build renovation, remodeling, project and construction management team serving Weston Wood Solutions: One of Canada’s fastest growing companies
An innovative supplier of lumber and engineered wood products to window and door manufacturers in the Americas, Europe CDW Canada: Helping organizations navigate a complex IT market
Established in 2003, CDW Canada is a leading provider of technology solutions for business, government, education, and healthcare,-
Reclaiming Canada’s key service export: Tourism
Tourism is an increasingly dynamic sector of the global economy; pre-2019 tourism was a $1.4 trillion industry generating Concerning signs for Canada’s construction sector in 2023
Coming into 2022, construction contractors had never been more optimistic about the state of the industry. Independent Contractors Strengthening your organization through sustainability & ESG
It’s no secret that organizations are increasingly feeling the pressure to respond to social and environmental imperatives. More 55% of provincial healthcare budgets will be for seniors by 2030
Canada’s straining health care system is dominating headlines, as provinces pit themselves against the federal government in a Spymasters, conspiracies, the PRC, & Dong Jingwei
The tensions currently exposed between the People’s Republic of China (PRC) and the United States, let alone the Digital transformations on the wrong end of the stick
There’s a growing body of evidence demonstrating technology-led digital transformations are overpromising and under-delivering returns on investment for It’s impossible to tackle climate change without nuclear
The task of tackling climate change is mammoth. It requires an ‘all-in’ approach among Canada’s business leaders, governments, Inflation: Demand creates its own supply
The point has to be made that while we clearly have a stickier inflation situation on our hands,
AstraZeneca and Aspen enter agreement for remaining rights to anaesthetics medicines
AstraZeneca has announced that it has entered into an agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
AstraZeneca entered into an agreement with AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US. Under the terms of the new agreement, AGI will now acquire the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines for an upfront consideration of $555 million. Additionally, AGI will pay AstraZeneca up to $211 million in performance-related milestones based on sales and gross margin during the period from 1 September 2017 to 30 November 2019. AstraZeneca will continue to manufacture and supply the medicines to AGI during a transition period of up to five years.
Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca said: “AstraZeneca, AGI and patients have all benefitted from the successful commercial agreement we established last year. As our relationship has evolved, AGI has shown that it is in a strong position to maximise the value and reach of the anaesthetic medicines through its extensive commercial network. Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas.”
Stephen Saad, Group Chief Executive, Aspen, said: “This second transaction allows AGI to reap the additional benefits from the excellent strategic acquisition that the anaesthetics portfolio has proven to be for Aspen and a key part of this will be to continue leveraging the strong working relationship that AGI has developed with AstraZeneca.”
Under the terms of the original agreement, entered into in June 2016, AGI made an upfront payment to AstraZeneca of $520 million and agreed to make future Product Sales-related payments of up to $250 million (see first payment below), as well as paying double-digit percentage royalties on Product Sales. AstraZeneca agreed to continue to manufacture and supply the medicines to AGI on a cost-plus basis for an initial period of 10 years.
The new agreement does not impact the first Product Sales-related payment of $150 million due to AstraZeneca, for which the contingent terms have now been met. This income will be recorded as Externalisation Revenue in the Company’s financial statements in the third quarter of 2017.
Under the new agreement, AGI will no longer pay royalties to AstraZeneca. The remaining $100 million Product Sales-related payment from the original agreement will be made to AstraZeneca in 2018, if the contingent terms are met, and will be recorded as Other Operating Income to reflect the reduced ongoing interest in the medicines as a result of the new agreement.
Further, as AstraZeneca will transition the manufacture and supply of the medicines to AGI, and therefore will have a reduced ongoing interest, the $555 million upfront and up to $211 million sales and gross margin-related payments from the new agreement will also be recorded as Other Operating Income in the Company’s financial statements.
The new, additional agreement is expected to close in the fourth quarter of 2017, subject to customary closing conditions and regulatory clearances. It does not impact AstraZeneca’s financial guidance for 2017.
- Read the current edition
- Recent posts
